DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
| Revenue (TTM) | $4.97B |
| Gross Profit (TTM) | $3.10B |
| EBITDA | $1.40B |
| Operating Margin | 24.30% |
| Return on Equity | 38.50% |
| Return on Assets | 10.30% |
| Revenue/Share (TTM) | $12.87 |
| Book Value | $6.95 |
| Price-to-Book | 12.91 |
| Price-to-Sales (TTM) | 6.68 |
| EV/Revenue | 6.7 |
| EV/EBITDA | 21.36 |
| Quarterly Earnings Growth (YoY) | 43.60% |
| Quarterly Revenue Growth (YoY) | 13.10% |
| Shares Outstanding | $377.36M |
| Float | $375.98M |
| % Insiders | 0.26% |
| % Institutions | 106.58% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Technical indicators have turned bullish for the three stocks.
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.
DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.
DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.
DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.
From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DXCM and any ticker you trade — then tracks every position and per-strategy win rate.
